Strategy

Time to engage with stem-cell therapeutics

Friday 27 April 2012

Interviewee/Contributer: Alain Vertès

Organisation: London Business School

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Interview: 4-Antibody AG - How do you structure a biotech for divestment?

Friday 27 April 2012

Interviewee/Contributer: Robert Burns

Organisation: 4-Antibody AG

Full text available to subscribers only. Click here for information on subscribing to MedNous.

A Big Pharma deal that shares risk and reward

Friday 27 April 2012

Interviewee/Contributer: Bahija Jalal

Organisation: MedImmune

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Focus on opthalmology: new treatment modality

Friday 27 April 2012

Interviewee/Contributer: Patrik de Haes

Organisation: ThromboGenics

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Due Diligence is more than a numbers game

Friday 27 April 2012

Interviewee/Contributer: Anthony Sedgwick

Organisation: Silence Therapeutics

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Kymab unlocks the power of the mouse

Saturday 24 March 2012

Interviewee/Contributer: Andrew Sandham

Organisation: Kymab Ltd

Full text available to subscribers only. Click here for information on subscribing to MedNous.

The role of technology providers in biotech

Friday 24 February 2012

Interviewee/Contributer: John Burt

Organisation: PolyTherics

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Risk sharing with Pharma -- is this the way to go?

Tuesday 15 November 2011

Interviewee/Contributer: Onno van de Stolpe

Organisation: Galapagos NV

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Partnering with Russia

Monday 24 October 2011

Interviewee/Contributer: John Mayo

Organisation: Celtic Pharma Holdings

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Innate Pharma's anti-cancer platform attracts BMS investment

Friday 15 July 2011

Interviewee/Contributer: Herve Brailly

Organisation: Innate Pharma SA

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Syndicate content